Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

BeyondSpring Inc

Healthcare US BYSI

1.74USD
0.04(2.35%)

Last update at 2026-06-03T20:00:00Z

Day Range

1.671.75
LowHigh

52 Week Range

1.213.44
LowHigh

Fundamentals

  • Previous Close 1.70
  • Market Cap71.55M
  • Volume13158
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.85800M
  • Revenue TTM1.88M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM 1.35M
  • Diluted EPS TTM-0.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.62500M -8.76900M -13.92300M -36.11700M -64.63800M
Minority interest 13.21M 5.57M 0.92M 3.00M 4.03M
Net income -7.99200M -11.12300M -21.02600M -36.28000M -68.20800M
Selling general administrative 4.56M 6.11M 10.23M 13.01M 30.70M
Selling and marketing expenses - - 0.30M - -
Gross profit -0.08700M -0.28500M -0.30200M 1.35M 1.35M
Reconciled depreciation 0.09M 0.28M 0.30M 0.23M 0.06M
Ebit -8.94500M -8.75400M -13.92300M -37.23900M -66.24000M
Ebitda -8.85800M -8.46900M -13.62100M -35.43900M -64.72100M
Depreciation and amortization 0.09M 0.28M 0.30M 1.80M 1.52M
Non operating income net other - - - - -
Operating income -8.94500M -8.75400M -15.08100M -37.23900M -66.24000M
Other operating expenses 8.95M 8.75M 15.08M 38.59M 67.59M
Interest expense - - 0.00000M 0.02M 0.09M
Tax provision 0.09M 0.10M 0.11M 0.16M 3.57M
Interest income 0.08M 0.06M 0.42M 0.20M 0.10M
Net interest income 0.08M 0.06M 0.42M 0.18M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.09M 0.10M 0.09M 0.16M 3.57M
Total revenue 0.00000M 0.00000M 1.75M 1.35M 1.35M
Total operating expenses 8.86M 8.75M 14.78M 38.59M 67.59M
Cost of revenue 0.09M 0.28M 0.30M - -
Total other income expense net 0.32M -0.01500M 1.16M 1.12M 1.60M
Discontinued operations - - - - -
Net income from continuing ops -8.71500M -8.86500M -21.94800M -36.28000M -68.20800M
Net income applicable to common shares - - - - -64.17900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 25.93M 34.31M 24.81M 46.22M 81.65M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 8.32M 25.66M 0.48M 0.76M 1.02M
Total liab 49.92M 48.60M 48.27M 49.23M 60.73M
Total stockholder equity -32.16100M -32.90000M -26.80500M -5.97900M 26.68M
Deferred long term liab - - - - -
Other current liab -15.70700M -16.96800M 4.17M 3.95M 10.02M
Common stock 0.00400M 0.00400M 0.00400M 0.00400M 0.00400M
Capital stock 0.00400M 0.00400M 0.00400M 0.00400M 0.00400M
Retained earnings -408.43100M -407.42500M -396.30200M -375.27600M -341.99700M
Other liab - - - - 38.65M
Good will - - - - -
Other assets - - 0.00000M - 3.12M
Cash 7.79M 2.92M 17.75M 34.40M 41.62M
Cash and equivalents - - - - -
Total current liabilities 13.58M 11.01M 7.96M 7.35M 15.15M
Current deferred revenue 28.60M 27.40M 1.75M 1.35M 1.37M
Net debt -7.46600M -2.33300M -13.75500M -29.43500M -38.05000M
Short term debt 0.32M 0.28M 0.63M 0.97M 2.11M
Short long term debt - - - - 1.57M
Short long term debt total 0.32M 0.59M 4.00M 4.96M 3.58M
Other stockholder equity 375.66M 373.19M 368.60M 368.86M 369.20M
Property plant equipment - - - - 3.41M
Total current assets 20.88M 28.58M 18.42M 38.52M 75.12M
Long term investments - - - - -
Net tangible assets - - - - 26.68M
Short term investments 4.78M 0.00000M 0.19M 2.87M 30.74M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.36M 0.29M 1.41M 1.08M 1.66M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.60M 1.34M 0.89M 0.44M -0.52300M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.58M 4.99M 0.36M 0.35M 1.57M
Deferred long term asset charges - - - - -
Non current assets total 5.05M 5.74M 6.39M 7.70M 6.53M
Capital lease obligations 0.32M 0.59M 4.00M 4.96M 2.01M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.48M -12.01200M -0.10000M 17.56M -20.41300M
Change to liabilities - - - 0.00000M 29.47M
Total cashflows from investing activities 13.48M -12.01200M -0.10000M - -20.41300M
Net borrowings 0.29M 3.91M 0.00000M - -
Total cash from financing activities 2.27M 26.79M 0.00400M 3.43M 0.00100M
Change to operating activities - - - 7.09M 0.19M
Net income -14.21700M -11.12300M -21.02600M -36.28000M -68.20800M
Change in cash 4.86M -1.70300M -16.64600M -7.22900M -67.91200M
Begin period cash flow 16.05M 17.75M 34.40M 41.62M 109.54M
End period cash flow 7.79M 16.05M 17.75M 34.40M 41.62M
Total cash from operating activities -20.02300M -16.44300M -16.47400M -27.46400M -47.24200M
Issuance of capital stock 2.00M 3.00M 0.00000M 0.00000M 0.00000M
Depreciation 0.09M 0.28M 0.30M 0.23M 0.06M
Other cashflows from investing activities 7.30M -11.78800M - - -
Dividends paid - - - - -
Change to inventory -0.01800M -0.01900M 0.19M - 1.77M
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 4.97M 22.87M 0.00400M 5.00M 0.00100M
Change to netincome - - - - -1.53200M
Capital expenditures 0.05M 0.22M 0.10M 0.03M 2.84M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.37600M -1.38100M 2.71M 6.41M 18.41M
Stock based compensation 0.72M 2.06M 0.55M 1.67M 3.15M
Other non cash items -6.23900M -6.28700M 0.99M 0.51M 0.55M
Free cash flow -20.07300M -16.66700M -16.57400M -27.49800M -50.08600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BYSI
BeyondSpring Inc		 0.04 2.35% 1.74 - 10.54 45.99 5.38 41.79 0.05
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

BeyondSpring Inc

100 Campus Drive, Florham Park, NJ, United States, 07932

Key Executives

Name Title Year Born
Dr. Lan Huang Co-Founder, Chairman & CEO 1971
Dr. G. Kenneth Lloyd Chief Scientific Officer 1944
Dr. Ramon W. Mohanlal Exec. VP of R&D, Chief Medical Officer and Director 1958
Mr. Linqing Jia Co-Founder NA
Stephen Kilmer Head of Investor Relations NA
Mr. Gregg Russo Sr. VP of HR NA
Dr. Lan Huang Ph.D. Co-Founder, Chairman & CEO 1971
Dr. June Lu Ph.D. Chief Scientific Officer NA
Mr. Gregg Russo Senior Vice President of Human Resources NA
Dr. June Lu Ph.D. Chief Scientific Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.